21 U.S.C. § 360e–1
(a)
New devices—
(2)
Required information— The application or protocol described in
paragraph (1) shall include, with respect to the
device for which approval is sought and if readily
available—
(A)
a description of any pediatric subpopulations that suffer from the disease or condition that the
device is intended to treat, diagnose, or cure; and
(B)
the number of affected pediatric patients.
(3)
Annual report— Not later than 18 months after September 27, 2007, and annually thereafter, the
Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and
Commerce of the House of Representatives a report that
includes—
(A)
the number of
devices approved in the year preceding the year in which the report is submitted, for which there is a pediatric subpopulation that suffers from the disease or condition that the
device is intended to treat, diagnose, or cure;
(B)
any information, based on a review of data available to the
Secretary, regarding
devices used in pediatric patients but not labeled for such use for which the
Secretary determines that approved pediatric
labeling could confer a benefit to pediatric patients;
(D)
the number of
devices approved in the year preceding the year in which the report is submitted, labeled for use in pediatric patients;
(G)
the number of
devices for which the
Secretary relied on data with respect to adults to support a determination of a reasonable assurance of safety and effectiveness in pediatric patients; and
(H)
the number of
devices for which the
Secretary relied on data from one pediatric subpopulation to support a determination of a reasonable assurance of safety and effectiveness in another pediatric subpopulation.
For the items described in this paragraph, such report shall disaggregate the number of devices by pediatric subpopulation.
(b)
Determination of pediatric effectiveness based on similar course of disease or condition or similar effect of device on adults—
(1)
In general— If the course of the disease or condition and the effects of the
device are sufficiently similar in adults and pediatric patients, the
Secretary may conclude that adult data may be used to support a determination of a reasonable assurance of effectiveness in pediatric populations, as appropriate.
(2)
Extrapolation between subpopulations— A study may not be needed in each pediatric subpopulation if data from one subpopulation can be extrapolated to another subpopulation.
Notes, amendments, and revision history
(June 25, 1938, ch. 675, § 515A, as added Pub. L. 110–85, title III, § 302, Sept. 27, 2007, 121 Stat. 859; amended Pub. L. 115–52, title V, § 502(a), Aug. 18, 2017, 131 Stat. 1037.)
Editorial Notes
Amendments
2017—Subsec. (a)(3). Pub. L. 115–52 added subpars. (B), (C), (G), and (H), redesignated former subpars. (B) to (D) as (D) to (F), respectively, substituted “(C), (D), and (E);” for “(B), and (C).” in subpar. (F), and inserted concluding provisions.
Statutory Notes and Related Subsidiaries
Final Rule Relating to Tracking of Pediatric Uses of Devices
Pub. L. 112–144, title VI, § 620(b), July 9, 2012, 126 Stat. 1064, provided that: “The Secretary of Health and Human Services shall issue— a proposed rule implementing section 515A(a)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e–1(a)(2)) not later than December 31, 2012; and a final rule implementing such section not later than December 31, 2013.”